Published in Lancet Oncol on August 01, 2002
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A (2004) 5.32
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A (2005) 4.12
In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A (2003) 3.19
Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol (2007) 2.56
Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res (2011) 2.26
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol (2009) 1.54
Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics (2009) 1.21
Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res (2008) 1.18
Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther (2009) 0.97
Basic principles and technologies for deciphering the genetic map of cancer. World J Surg (2009) 0.96
Prostate cancer stem cells. Clin Genitourin Cancer (2012) 0.96
Origins and clinical implications of the brain tumor stem cell hypothesis. J Neurooncol (2009) 0.92
Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl Med Mol Imaging (2006) 0.86
Putative biomarkers and targets of estrogen receptor negative human breast cancer. Int J Mol Sci (2011) 0.85
Cancer: a "stem-cell" disease? Cancer Cell Int (2013) 0.85
Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction. Front Oncol (2013) 0.83
The involvement of adult stem cells originated from bone marrow in the pathogenesis of pterygia. Yonsei Med J (2005) 0.83
Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol (2010) 0.82
Stem cell origin of testicular seminoma. Clin Genitourin Cancer (2013) 0.81
A retrospective review of the prognostic value of ALDH-1, Bmi-1 and Nanog stem cell markers in esophageal squamous cell carcinoma. PLoS One (2014) 0.81
The tiny world of microRNAs in the cross hairs of the mammalian eye. Hum Genomics (2009) 0.80
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer (2016) 0.79
Epithelial ovarian cancer stem cells-a review. Int J Clin Exp Med (2008) 0.79
Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget (2015) 0.79
Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. Cytotechnology (2012) 0.79
Gene methylation of human ovarian carcinoma stromal progenitor cells promotes tumorigenesis. J Transl Med (2015) 0.78
Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng (2015) 0.78
Role of stromal-epithelial interaction in the formation and development of cancer cells. Cancer Microenviron (2013) 0.76
Cancer Stem Cells and the Bone Marrow Microenvironment. Bonekey Rep (2012) 0.76
Variant prostate carcinoma and elevated serum CA-125. Can J Urol (2014) 0.75
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget (2016) 0.75
TLX-Its Emerging Role for Neurogenesis in Health and Disease. Mol Neurobiol (2016) 0.75
Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migration. Oncotarget (2016) 0.75
Sorting and biological characteristics analysis for side population cells in human primary hepatocellular carcinoma. Am J Cancer Res (2016) 0.75
MicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinoma. BMC Cancer (2016) 0.75
Recent developments in the management of germ cell tumors. Curr Opin Oncol (2017) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab (2005) 1.99
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res (2004) 1.59
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 1.46
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res (2008) 1.30
NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol (2006) 1.30
Bortezomib as a potential treatment for prostate cancer. Cancer Res (2004) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. J Cell Sci (2003) 1.21
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics (2009) 1.11
Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem (2004) 1.10
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A (2011) 1.09
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis (2002) 1.08
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res (2007) 1.07
Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res (2004) 1.06
Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proc Natl Acad Sci U S A (2011) 1.06
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol (2002) 1.06
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.05
Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol (2010) 1.04
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res (2002) 1.04
Biology and clinical management of prostate cancer bone metastasis. Front Biosci (2007) 1.04
Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol (2004) 1.03
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol (2005) 1.03
CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. J Clin Invest (2004) 1.02
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res (2007) 1.00
16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res (2007) 1.00
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Inform (2007) 0.99
The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev (2006) 0.99
Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep (2003) 0.99
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res (2005) 0.98
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
Prostate cancer stem cells. Clin Genitourin Cancer (2012) 0.96
Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. Protein Expr Purif (2008) 0.96
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res (2004) 0.95
Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One (2013) 0.95
Prioritizing genes associated with prostate cancer development. BMC Cancer (2010) 0.94
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int (2009) 0.94
Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells. Oncogene (2002) 0.94
Inhibition of FOXO3 tumor suppressor function by betaTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS One (2010) 0.93
Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov (2011) 0.93
Acetylation of RNA processing proteins and cell cycle proteins in mitosis. J Proteome Res (2010) 0.93
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res (2004) 0.93